Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12144MR)

This product GTTS-WQ12144MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12144MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3645MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ8170MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ11804MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14089MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ11351MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ1046MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ885MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ10371MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW